Latest News

The objective of this study was to describe bladder cancer outcomes as a function of race among patients with high-risk non-muscle-invasive bladder cancer (NMIBC) in an equal-access setting. A total of 412 patients with high-risk NMIBC who received bacille Calmette-Guérin (BCG) from January 1, 2010, to December 31, 2015, were assessed.

Prostatic artery embolization (PAE) is an effective therapy for alleviating lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia; however, is not well studied in patients with concurrent prostate cancer (PCa).

Prostate cancer (PCa) is the second most common cancer amongst men in the United States. While the use of PSA has improved the ability to screen and ultimately diagnose PCa, there still remains false positives due to non-cancerous conditions in the prostate gland itself and other prognostic biomarkers for PCa are needed.

The aim of this study was to evaluate the changes in lesion volume on serial multiparametric magnetic resonance (mpMRI) during active surveillance for prostate cancer. A total of 160 patients with a targeted biopsy-confirmed visible lesion on mpMRI, stratified by low- and intermediate-risk disease (Gleason Grade Group 1 vs Gleason Grade Group 2), were analysed.

(UroToday.com) It is now well established that PSMA PET/CT is more sensitive than conventional imaging. As such, PET/CT scan might lead to the identification of nodal metastases (e.g., cN1) in prostate cancer (PCa) patients considered for radical prostatectomy (RP). However, there is no data addressing the performance characteristics and prognostic value of a positive PET/CT in […]

(UroToday.com) In this study, Dr. Neal Shore and colleagues evaluate the impact of late dosing on testosterone suppression with two different leuprolide acetate formulations: In situ gel and microsphere.

(UroToday.com) Darolutamide (DARO) is a structurally distinct androgen receptor inhibitor (ARI) that has been demonstrated to significantly prolong metastasis-free survival and overall survival in the ARAMIS trial.1

(UroToday.com) Darolutamide (DARO) is a structurally distinct androgen receptor inhibitor (ARI) that has been demonstrated to significantly prolong metastasis-free survival and overall survival in the ARAMIS trial.1

(UroToday.com) In this abstract, the authors evaluate the utility of ultra-fast biparametric MRI for prostate cancer detection. Multiparametric MRI (mpMRI) of the prostate is the imaging modality of choice for the early detection of prostate cancer (PCa) in men with clinical suspicion. However, mpMRI can be costly and time-consuming. mpMRI of the prostate typically has […]

(UroToday.com) The treatment for metastatic hormone-sensitive prostate cancer plenary session at the European Association of Urology 2021 Annual Meeting included a presentation by Dr. Christopher Sweeney discussing when and how to use systemic treatment for recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney notes that the hypothesis is that men with mHSPC have a wide array […]